Last reviewed · How we verify
NCT04962451
Comparison of the Efficacy of Ticagrelor Combined With ASA to ASA Alone in Patients With Stroke
Phase 4 trial testing ticagrelor + ASA in Cerebrovascular Accident in 13,000 participants. Completed in 31 October 2019.
30 September 2019
Quick facts
| Lead sponsor | Peking University Third Hospital |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 13,000 |
| Start date | 1 September 2017 |
| Primary completion | 30 September 2019 |
| Estimated completion | 31 October 2019 |
| Sites | 1 location across China |
Drugs / interventions tested
- ticagrelor + ASA — full drug profile →
- Placebo+ASA — full drug profile →
Conditions studied
- Cerebrovascular Accident — all drugs for Cerebrovascular Accident →
- Cerebrovascular Accident, Acute — all drugs for Cerebrovascular Accident, Acute →
Sponsor
Peking University Third Hospital
Who can join
40 and older, any sex, with Cerebrovascular Accident or Cerebrovascular Accident, Acute. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Cerebrovascular disease is the main cause of death and severe long-term disability worldwide. Antiplatelet drugs are the main drugs for ischemic stroke and TIA. Cyclooxygenase inhibitor acetylsalicylic acid (ASA) has always been the most widely studied antiplatelet therapy. The studies of acrates of aliscon body evaluated the efficacy and safety of ticagrelor monotherapy in preventing major vascular events in patients with AIS or TIA. The results showed that the number of patients with endpoint events in ticagrelor group was less than that in ASA group, However, it has not been proved that ticagrelor monotherapy is better than ASA. The purpose of this study is to prove that ticagrelor is better than ASA.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The Translational Potential of Microglia and Monocyte-Derived Macrophages in Ischemic Stroke.
Wicks EE, Ran KR, Kim JE, Xu R, et al · · 2022 · cited 68× · PMID 35795678 · DOI 10.3389/fimmu.2022.897022
Verify or expand the search:
- PubMed search for NCT04962451
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cerebrovascular Accident
Currently open trials in the same condition.
- NCT07272239 — Effects of tVNS and mCIMT in Chronic Stroke · NA · recruiting
- NCT06498011 — COgnitive-somatoSensory-MOtor Training to Improve Arm and Hand Function After Stroke (iCOSMO) · NA · recruiting
- NCT06521801 — Cardio-Renal Registry · recruiting
- NCT06371937 — iPSC Biobank of Biomarkers Diversity in Cardiovascular Disease · recruiting
- NCT06107010 — Effects of Atalante Exoskeleton on Gait Recovery in Non- or Poorly Ambulatory Patients With Hemiparesis in the Acute/Sub · NA · recruiting
Other Peking University Third Hospital trials
Trials by the same sponsor.
- NCT07532421 — Probiotic Intervention on the Development of Allergic Diseases in Infants Exposed to Antibiotics Early in Life · NA · not yet recruiting
- NCT07470255 — Detection of Diabetic Foot Skin Damage Using Plantar Mechanical Parameters · not yet recruiting
- NCT07453381 — Multisensor Wireless Pressure Microcatheter For Microvascular Function Assessment In ANOCA/INOCA Patients: A Prospective · not yet recruiting
- NCT07452354 — AI-Based Diabetic Foot Recurrence Cohort · not yet recruiting
- NCT07423819 — Sports Rehabilitation Therapy for Knee Joint Sports Injuries: A Case Study of Anterior Cruciate Ligament Injury and Pate · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04962451 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking University Third Hospital
- Last refreshed: 15 July 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04962451.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing